Over the past few years, PSMA-PET has become a favourable non-invasive imaging method for the diagnosis of prostate cancer by outperforming choline-PET, in particular for recurrent disease with low PSA levels [1,2,3,4,5,6]. This evidence concerns the gene FOLH1 and prostate carcinoma.